医保商保双“目录”发布

Core Insights - The release of the 2025 National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug Catalog, along with the first edition of the Commercial Health Insurance Innovative Drug Catalog, marks a significant step in building a multi-tiered medical security system and supporting the development of the innovative drug industry in China [1] Group 1: Medical Insurance Coverage Expansion - The adjusted National Medical Insurance Drug Catalog now includes a total of 3,253 drugs, comprising 1,857 Western medicines and 1,396 traditional Chinese medicines [2] - The 2025 National Medical Insurance Drug Catalog includes drugs that fill gaps in basic medical insurance coverage for major diseases such as triple-negative breast cancer, pancreatic cancer, and lung cancer, as well as rare diseases and chronic conditions [2] - Notable companies like Innovent Biologics and Jiangsu Hengrui Medicine have multiple innovative products included in the 2025 catalog, covering various fields such as oncology and metabolic diseases [2] Group 2: Commercial Health Insurance Innovative Drug Catalog - The first edition of the Commercial Health Insurance Innovative Drug Catalog includes 19 drugs, focusing on high-innovation treatments for conditions like cancer, rare diseases, and Alzheimer's disease [3] - The introduction of this catalog aims to provide a transitional solution for high-priced innovative drugs that cannot be included in the basic medical insurance catalog, ensuring patient access to necessary treatments [3] Group 3: Policy and Capital Resonance - Recent policies have increasingly supported innovative drugs and medical devices, with 835 new drugs added to the medical insurance payment scope over the past seven years, including 149 innovative drugs [4] - The introduction of the Commercial Health Insurance Innovative Drug Catalog is seen as a crucial measure to address payment challenges and promote a diversified payment system [4] - Companies are encouraged to focus on developing clinically valuable drugs, leveraging their strengths in innovation and manufacturing [4] Group 4: Industry Outlook - The pharmaceutical industry is expected to enter a new phase of policy stabilization, industrial upgrading, and internationalization over the next five years, with the potential for high industry prosperity [6]